Company Description: Minutia is developing a regenerative medicine platform that improves safety and success outcomes of transplanted cells, our first therapy is a functional cure for Type 1 and Insulin Dependent Type 2 Diabetes with a simple outpatient procedure. We have already successfully demonstrated our out-patient transplant procedure in a PI-led Phase 1/2 clinical trial at UCSF, and are progressing our nanoparticle instrumented stem cell platform to enable safety and personalization across the broader cell therapy market.